Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,227 recruiting studies in this area right now.
By phase
- Not applicable3,140
- Phase 21,067
- Phase 1822
- Phase 1/Phase 2446
- Phase 3423
- Phase 4236
- Phase 2/Phase 393
Top conditions
- Multiple Sclerosis342
- Multiple Myeloma333
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis142
- Type 1 Diabetes132
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia123
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Leukemia64
- Rheumatoid Arthritis (RA)64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- Novartis Pharmaceuticals65
- M.D. Anderson Cancer Center63
- AstraZeneca57
- City of Hope Medical Center46
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama176
- Florida143
- Arizona140
- New York122
- Massachusetts119
- Texas118
- Illinois82
- Colorado77
Recruiting studies6,227 total
- NCT06669247RecruitingPhase 1/Phase 2
Study of REGN7945 plus linvoseltamab for relapsed or refractory multiple myeloma
This study tests a new combination of two drugs (REGN7945 and linvoseltamab) for people with multiple myeloma that has come back or not responded to at least 3 prior treatments. The goal is to see if the combination is safe and effective, and it may offer a new option if other therapies have stopped working.
Sydney, New South WalesAges 18 years+ - NCT07745530Recruiting
How platelets affect HIV reservoirs in the blood
This study looks at how platelets (small blood cells that help with clotting) might influence the hidden HIV that remains in your body even when your viral load is undetectable. The goal is to understand why some people's immune systems don't fully recover despite effective HIV treatment.
TourcoingAges 18 years+ - NCT07745907RecruitingPhase 1
A first-in-human study of a new drug in healthy Chinese and Japanese adults
This trial tests a single dose of an investigational drug called AMG 691 in healthy Chinese and Japanese volunteers to see how it is processed by the body and how safe it is. This is an early-phase study, so it may help make future treatments safer for people of similar backgrounds.
Las Vegas, NevadaAges 18–60 - NCT07745426RecruitingPhase 2
Comparing add-on treatments for rheumatoid arthritis
This trial compares two additional medicines (diosmin or rebamipide) taken with standard arthritis treatment to see if they help reduce joint pain and swelling better than standard treatment alone.
TantaAges 18–70 - NCT03739814RecruitingPhase 2
Test inotuzumab, blinatumomab, and possibly ponatinib for CD22 ALL
This Phase 2 study tests a combination of medicines (inotuzumab ozogamicin and blinatumomab), with or without ponatinib, for people with CD22-positive B-cell acute lymphoblastic leukemia (ALL). It aims to improve remission and control leukemia cells, including in the bone marrow.
Birmingham, AlabamaAges 18 years+ - NCT06849713RecruitingPhase 2
New combination treatments for CLL or SLL
This trial tests two different combinations of targeted drugs for people with CLL or SLL who have not had prior treatment for their disease. The goal is to see if these combinations are safe and effective.
Boston, MassachusettsAges 18 years+ - NCT07573111RecruitingPhase 1
QUAIL-100 for Children With Blood Cancers After Stem Cell Transplant
This study tests a new experimental treatment called QUAIL-100 in children and young adults who have had a stem cell transplant for a serious blood cancer. The treatment is designed to help the immune system fight remaining cancer cells.
Palo Alto, CaliforniaAges 1.5 years–39 years - NCT06617793RecruitingPhase 1/Phase 2
Testing YTB323 for active relapsing multiple sclerosis
This trial tests a new cell therapy called YTB323 for people with relapsing multiple sclerosis (RMS) that is still active despite strong treatments. The treatment aims to reset the immune system to stop attacks on nerves.
Darlinghurst, New South WalesAges 18–60 - NCT06441331RecruitingPhase 1
Lu-177 edotreotide for children with SSTR-positive tumors
This trial tests a radioactive drug called Lu-177 edotreotide for children with a certain type of tumor (SSTR-positive) that hasn't responded to other treatments. The goal is to find the right dose and see how safe it is.
San Francisco, CaliforniaAges 2–18 - NCT06419205RecruitingPhase 2
ADX-097 for IgA nephropathy, lupus nephritis, or C3G
This study tests an experimental oral therapy called ADX-097 for people with three types of kidney disease: IgA nephropathy, lupus nephritis, or C3 glomerulopathy. The goal is to see if it’s safe and can help reduce kidney damage.
Lawrenceville, GeorgiaAges 16 years+ - NCT07744425Enrolling by invitation
Surgical imaging device study
This study tests a new camera that helps surgeons see tissues more clearly during surgery. It may help improve surgical precision and safety.
Palo Alto, CaliforniaAges 18–90 - NCT07188558RecruitingPhase 3
Comparing ronde-cel to standard CAR T-cell therapy for large B-cell lymphoma
This trial tests a new treatment called ronde-cel against the usual CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to see if ronde-cel works better.
Gilbert, ArizonaAges 18 years+ - NCT06244212Recruiting
Atopic dermatitis treatment with steroid cream trial
This trial tests a common steroid cream (triamcinolone) for atopic dermatitis (a type of eczema). It aims to see how well it works in people who have active skin inflammation and can come back for a follow-up visit one week later.
Winston-Salem, North CarolinaAges 9 years+ - NCT06994520Enrolling by invitationPhase 2
Topical cannabis extract for eczema itch
This study tests a cannabis-based cream on eczema-related itch over 4 weeks. It may help reduce itching if other treatments haven't worked, but requires pausing other skin products during the trial.
Khon Kaen, Changwat Khon KaenAges 25 years+ - NCT07264959Recruiting
A study on indolent systemic mastocytosis treatments
This study is observing adults with indolent systemic mastocytosis (ISM) who are already receiving or planning to start symptom treatments or the drug avapritinib. It aims to learn more about how these treatments work in real life.
Wheaton, MarylandAges 18 years+ - NCT04910685RecruitingPhase 2/Phase 3
BLU-263 for indolent mast cell disease with symptom control
This trial tests BLU-263, a study medicine, against placebo (inactive treatment) to see if it improves symptoms in people with indolent systemic mastocytosis. It also checks safety and how well the dose is tolerated before and during treatment.
Birmingham, AlabamaAges 18 years+ - NCT07742215RecruitingPhase 3
Combination treatment for relapsed or refractory multiple myeloma
This trial tests a new drug (BCD-248) combined with daratumumab for people whose multiple myeloma has come back or stopped responding to previous treatments. The goal is to see if this combination can help control the cancer better.
HomyelAges 18 years+ - NCT07134686Recruiting
Combined lung and ear-nose-throat care for asthma and sinusitis
This trial tests if seeing a lung specialist and an ear-nose-throat doctor together in one visit helps people with asthma and chronic sinusitis (with nasal polyps) feel better than seeing each specialist separately. You may qualify if your asthma or sinusitis is not well-controlled and you've used steroid pills in the past year.
MarseilleAges 18 years+ - NCT07742306Recruiting
Glucose monitor study for teens with type 1 diabetes
This study tests using a continuous glucose monitor (CGM) in teenagers with type 1 diabetes in the Dominican Republic. The device tracks blood sugar levels around the clock to help manage their diabetes better. Participants will get support and education over about 15 months.
Santiago de los CaballerosAges 10–19 - NCT07743242Recruiting
Study of hemolytic anemia in antiphospholipid syndrome
This study looks at how autoimmune hemolytic anemia (when the body attacks its own red blood cells) relates to antiphospholipid syndrome (a condition that increases blood clot risk). It aims to better understand this connection, which may help improve care for people with both conditions.
Al Khārjah, Kharga OasisAges 18 years+ - NCT07203404RecruitingEarly Phase 1
A study of a universal CAR-T cell therapy for autoimmune diseases
This trial tests a new treatment called RD06-05, which uses specially engineered immune cells to target and potentially reset parts of the immune system that are attacking your own body. It is being studied for several autoimmune conditions like lupus, vasculitis, kidney diseases, and more.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07634653Recruiting
Strength Training for Kids with Newly Diagnosed Blood Cancer
This study tests whether strength training exercises during cancer treatment can help children with acute lymphoblastic leukemia or lymphoblastic lymphoma feel stronger and recover better. The research includes optional interviews with parents to understand how the program affects families.
Chapel Hill, North CarolinaAges 6 years+ - NCT06046833Recruiting
Continuous glucose monitoring for diabetic gastroparesis
This study tests whether a continuous glucose monitor (CGM) can help manage blood sugar in people with diabetes and gastroparesis (slow stomach emptying). If you have type 1 or type 2 diabetes and stomach symptoms, this could help doctors better understand your glucose patterns.
Cleveland, OhioAges 18 years+ - NCT06654882RecruitingPhase 3
Switching medications after first treatment fails in juvenile arthritis
This study tests different medication sequences for children and teens with polyarticular juvenile idiopathic arthritis (JIA) who still have moderate or high disease activity after at least 3 months on their first tumor necrosis factor inhibitor (TNFi) therapy. The goal is to find the best next step to control symptoms and improve quality of life.
San Francisco, CaliforniaAges 2–17
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,227 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,696 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.